

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7827681

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PROCLARA BIOSCIENCES INC.	06/01/2022
RECEIVING PARTY DATA	
Name:	AMYL THERAPEUTICS SRL
Street Address:	98 RUE DE LA CENSE ROUGE
City:	LIEGE
State/Country:	BELGIUM
Postal Code:	4031
PROPERTY NUMBERS Total: 5	
Property Type	Number
Patent Number:	9493515
Patent Number:	9493516
Patent Number:	9688728
Patent Number:	9988444
Application Number:	16905128
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2024084000
Email:	faxserve@finnegan.com
Correspondent Name:	FINNEGAN HENDERSON LLP
Address Line 1:	901 NEW YORK AVENUE NORTHWEST
Address Line 2:	FINNEGAN
Address Line 4:	WASHINGTON, D.C. 20001
ATTORNEY DOCKET NUMBER:	12236.0007-01000
NAME OF SUBMITTER:	BENJAMIN HEMMELGARN
SIGNATURE:	/Benjamin Hemmelgarn/
DATE SIGNED:	03/03/2023
Total Attachments: 39	

source=NP4-7 Assignment 12236.0004 - 0007#page1.tif
source=NP4-7 Assignment 12236.0004 - 0007#page2.tif
source=NP4-7 Assignment 12236.0004 - 0007#page3.tif
source=NP4-7 Assignment 12236.0004 - 0007#page4.tif
source=NP4-7 Assignment 12236.0004 - 0007#page5.tif
source=NP4-7 Assignment 12236.0004 - 0007#page6.tif
source=NP4-7 Assignment 12236.0004 - 0007#page7.tif
source=NP4-7 Assignment 12236.0004 - 0007#page8.tif
source=NP4-7 Assignment 12236.0004 - 0007#page9.tif
source=NP4-7 Assignment 12236.0004 - 0007#page10.tif
source=NP4-7 Assignment 12236.0004 - 0007#page11.tif
source=NP4-7 Assignment 12236.0004 - 0007#page12.tif
source=NP4-7 Assignment 12236.0004 - 0007#page13.tif
source=NP4-7 Assignment 12236.0004 - 0007#page14.tif
source=NP4-7 Assignment 12236.0004 - 0007#page15.tif
source=NP4-7 Assignment 12236.0004 - 0007#page16.tif
source=NP4-7 Assignment 12236.0004 - 0007#page17.tif
source=NP4-7 Assignment 12236.0004 - 0007#page18.tif
source=NP4-7 Assignment 12236.0004 - 0007#page19.tif
source=NP4-7 Assignment 12236.0004 - 0007#page20.tif
source=NP4-7 Assignment 12236.0004 - 0007#page21.tif
source=NP4-7 Assignment 12236.0004 - 0007#page22.tif
source=NP4-7 Assignment 12236.0004 - 0007#page23.tif
source=NP4-7 Assignment 12236.0004 - 0007#page24.tif
source=NP4-7 Assignment 12236.0004 - 0007#page25.tif
source=NP4-7 Assignment 12236.0004 - 0007#page26.tif
source=NP4-7 Assignment 12236.0004 - 0007#page27.tif
source=NP4-7 Assignment 12236.0004 - 0007#page28.tif
source=NP4-7 Assignment 12236.0004 - 0007#page29.tif
source=NP4-7 Assignment 12236.0004 - 0007#page30.tif
source=NP4-7 Assignment 12236.0004 - 0007#page31.tif
source=NP4-7 Assignment 12236.0004 - 0007#page32.tif
source=NP4-7 Assignment 12236.0004 - 0007#page33.tif
source=NP4-7 Assignment 12236.0004 - 0007#page34.tif
source=NP4-7 Assignment 12236.0004 - 0007#page35.tif
source=NP4-7 Assignment 12236.0004 - 0007#page36.tif
source=NP4-7 Assignment 12236.0004 - 0007#page37.tif
source=NP4-7 Assignment 12236.0004 - 0007#page38.tif
source=NP4-7 Assignment 12236.0004 - 0007#page39.tif

ASSET PURCHASE AGREEMENT

This ASSET PURCHASE AGREEMENT (this "Agreement") is made and entered into as of June 1, 2022 (the "Effective Date"), by and among Amyl Therapeutics SRL, a company registered under the laws of Belgium, having its registered offices at 98 rue de la Cense rouge, 4031 Liège, Belgium, and registered with the register of legal entities under number 0758.775.372. (RLE Liège, section Liège), duly represented by the undersigned, ("Amyl Tx" and/or "Buyer"), and Proclara Biosciences Inc., a Delaware corporation, having its registered offices at 57 W. 57th Street, New York, NY 10019, United States, duly represented by the undersigned ("Proclara" and/or "Seller"). Buyer and Seller may be referred to herein collectively as the "Parties" and individually as a "Party".

RECITALS

WHEREAS, Seller has and owns all rights, title and interest in and to the Assigned IP (as defined below);

WHEREAS, Seller desires to sell to Buyer and Buyer desires to purchase from the Seller all rights, title and interest in and to the Assigned IP all in accordance with the terms and conditions of this Agreement;

WHEREAS, the Parties have entered into an IP Assignment and License Agreement effective as of March 26, 2021 (the "IP Assignment and License Agreement") under which, inter alia, Proclara assigned to Amyl Tx the NP9 Assets and the NP9 IP (as defined thereunder) and granted Amyl Tx a license under certain assets within the Assigned IP (as defined below) on an exclusive basis within the Field (as defined thereunder) and on a non-exclusive basis outside the Field (the "License"), together with an option to acquire the Proclara Background IP (as defined therein) (the "Option");

WHEREAS, Amyl Tx, desires to exercise the Option referenced above, and the Parties desire to reflect the fact that certain Assigned IP that currently is licensed under the IP Assignment Agreement is now being assigned to Buyer; and

WHEREAS, the Parties desire to make certain representations, warranties, covenants and agreements;

NOW, THEREFORE, in consideration of the representations, warranties, covenants and agreements set forth herein, and for other good and valuable consideration, the Parties, intending to be legally bound, agree as follows:

ARTICLE I DEFINITIONS

1.1 Certain Defined Terms. As used in this Agreement, the following terms shall have the following meanings:

[REDACTED]

"Agreement" has the meaning set forth in the Preamble.

[REDACTED]

"Assigned IP" means the Assigned Patents [REDACTED]

[REDACTED]

[REDACTED]

“Assigned Patents” means the patent applications and patents set forth on Schedule 2, any resulting patents, any of Seller’s additional patent applications or issued patents that disclose Assigned IP, and all continuations, continuations-in-part, substitutions renewals, divisionals, reissues, reexaminations and extensions, confirmations, validations, re-validations and all patents granted thereon, patents-of-addition, restorations by existing or future extension or restoration mechanisms, including, without limitation, supplementary protection certificates or the equivalent thereof and any foreign counterparts related to any of the foregoing, and any Patent Rights claiming priority to any of the foregoing in any jurisdiction. For clarity, the Assigned Patents are the patent and patent applications identified in Annex B as “NP4A”, “NP4B”, NP6” and “NP7” and are the same patent and patent applications in the Proclara Background IP (as defined in the IP Assignment and License Agreement).

[REDACTED]

“Buyer” has the meaning set forth in the Preamble.

[REDACTED]

[REDACTED]

“Effective Date” shall have the meaning set forth in the Preamble.

[REDACTED]

[REDACTED]

“IP Rights” means any and all of the following in any country: Patent Rights, [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

“Party” and “Parties” have the meaning set forth in the Preamble.

“Patent Rights” means (a) patent applications, including any provisional patent applications, in any country or under any international treaty, convention, or jurisdiction; (b) any patent application claiming priority from or the benefit of such patent application in (a) or provisional application, including all

divisionals, continuations, substitutions, continuations-in-part, provisionals, converted provisionals and continued prosecution applications; (c) any patent that has issued or in the future issues from any of the foregoing patent applications, ((a) and (b)), including any utility model, petty patent, design patent, and certificate of invention; (d) any re-examinations, reissues, additions, renewals, extensions, including patent term extensions, restorations, registrations, supplemental protection certificates, of any of the foregoing patents or patent applications ((a), (b), and (c)); (e) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent application or patent; and (f) all rights and priorities afforded under any Applicable Law with respect to any of the foregoing.

[REDACTED]

“Preamble” means the preamble of this Agreement.

[REDACTED]

[REDACTED]

“Seller” has the meaning set forth in the Preamble.

[REDACTED]

[REDACTED]

ARTICLE II

SALE AND PURCHASE OF ASSIGNED IP

2.1 Purchase and Sale. Upon and subject to the terms and conditions hereof, as of the Effective Date, Buyer shall purchase from Seller, and Seller shall sell, convey, assign, transfer and deliver to Buyer,

all assets, properties, rights, titles and interests of every kind and nature in, to and under the Assigned IP. Seller hereby assigns all right, title and interest in Assigned IP to Buyer. Following signature of this Agreement, Assigned IP and all improvements thereto shall be the proprietary and confidential information of Buyer (and, for clarity, Proclara Background IP, as defined under the IP Assignment and License Agreement, shall cease to be licensed to Buyer under the IP Assignment and License Agreement).

[REDACTED]

[REDACTED]

2.4 Deliverables.

(a) Deliveries by Seller. On the Effective Date, Seller shall deliver, or cause to be delivered, to Buyer, each of the following items, duly executed by Seller (or its applicable Affiliate or other related Person). For clarity, the delivery may be effected remotely via the electronic exchange of executed documents and other deliverables to the following address or alternate means mutually agreed by the Parties:

(i) the Assigned IP in the manner and form and to the locations reasonably specified by Buyer, such instruments of transfer, conveyance or assignment necessary, to the Buyer's satisfaction, for the transfer of all of Seller's rights, title and interest in, to and under the Assigned IP, including all documents confirming that assignment of Assigned Patents have been duly filed with all relevant patent offices;

[REDACTED]

[REDACTED]

[REDACTED]

■ [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]
 [REDACTED]
 [REDACTED]

[illegible]

§ 87(2)(b) § 87(2)(b) § 87(2)(b)

§ 87(2)(b) § 87(2)(b) § 87(2)(b)

§ 87(2)(b) § 87(2)(b) § 87(2)(b)

§ 87(2)(b) § 87(2)(b) § 87(2)(b)

[REDACTED]

ARTICLE III
REPRESENTATIONS AND WARRANTIES OF SELLER

The Seller hereby represents and warrants to Buyer, as of the Effective Date, as follows:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

3.6 Seller solely and exclusively (or with its Affiliates) owns all right, title and interest in, to and under all Assigned IP, free and clear of all Liens. [REDACTED]

[REDACTED] Seller is not a party to any contract which has granted, or resulted in the transfer of, any IP Rights with respect to the Assigned IP or Programs to a third party. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby will not result in the loss, forfeiture, termination, license, or impairment of, or give rise to any obligation to transfer or to create, change or abolish, or limit, terminate, or consent

to the continued use of any rights in any Assigned IP. To the Knowledge of the Seller no Assigned IP are or have been the subject of any Action or any judicial, administrative or arbitral order, judgment, award, order, decree, injunction, settlement or stipulation that bars or limits the use of such rights (excluding rejections, orders or rulings issued in the context of the application for registration of the Assigned IP), including any Action involving any claim that Seller infringed, misappropriated, diluted or otherwise violated the IP Rights of any third party.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

ARTICLE IV

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

ARTICLE V
ADDITIONAL AGREEMENTS

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

5.3 Transfer of Assigned IP; Notification. In the event that it is discovered by Seller or any of its Affiliates or identified to Seller in writing by Buyer at any time after the Effective Date, that possession or ownership of any Assigned IP has not been transferred to, or assumed by, either Buyer or its Affiliates as of such time, Seller shall promptly take such steps as may be required to transfer or assign, or cause to be transferred or assigned, such Assigned IP to Buyer or its Affiliates and otherwise in accordance with the terms of this Agreement, at no additional charge to Buyer or its Affiliates, and Buyer or its Affiliates shall accept such Assigned IP, as the case may be.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

ARTICLE VI

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

■ [REDACTED]

■ [REDACTED]

[REDACTED]

■ [REDACTED]

[REDACTED]

■ [REDACTED]

[REDACTED]

■ [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

ARTICLE VIII
GENERAL PROVISIONS

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

8.2 Counterparts; Electronic Signatures. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Each Party certifies that the policies of such Party do not prohibit the acceptance and execution of this Agreement in electronic form. In addition to the foregoing, the Parties consent to, and agree that, the use of a keyboard, mouse, or other device to affix an electronic signature to this Agreement constitutes a lawful and valid signature, acceptance, and agreement, and shall be treated the same as if such were made using a manual, written signature. The Parties additionally agree that no certification authority, or other third party verification, is necessary to validate their respective electronic signature, and that the lack of such certification, or third party verification, will not in any way affect the validity or enforceability of such signature or any resulting agreement. At the request of either Party or to any such agreement or instrument, the other Party hereto or thereto will re-execute original forms thereof and deliver them to the other Party.

8.3 Entire Agreement; Non-assignability; Parties in Interest.

(a) This Agreement, the documents and instruments delivered pursuant to this Agreement, including schedules and the Disclosure Schedule together constitute the entire agreement among the Parties with respect to the subject matter hereof and supersede all prior agreements and understandings, both written and oral, among the Parties with respect to the subject matter hereof. For clarity, terms of the IP Assignment and License Agreement applicable to NP9 Assets and NP9 IP (each as defined in such agreement) shall remain in full force and effect. Notwithstanding the foregoing, following the Effective Date, Buyer shall have no further obligation to Seller under the IP Assignment and License Agreement or annexes thereto.

(b) This Agreement and the documents and instruments delivered pursuant to this Agreement, including schedules and the Disclosure Schedule together, shall not be assigned by Seller (by

operation of law or otherwise) without the written consent of Buyer, which consent shall not unreasonably be withheld, conditioned or delayed (and any purported assignment in violation of this Agreement shall be void); and the rights and obligations of Buyer may be freely assigned.

(c) This Agreement is not intended to, and does not, confer upon any Person other than the Parties who are signatories hereto any rights or remedies hereunder.

■ [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED] [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]
■ [REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]
■ [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, each of the undersigned has executed this Asset Purchase Agreement as an agreement as of the Effective Date.

BUYER:

AMYL THERAPEUTICS SRL

By: 

Name:

Pierro VAN DE CAPELLE

Title:

CEO

SELLER:

PROCLARA BIOSCIENCES INC.

By: _____

Name: _____

Title: _____

IN WITNESS WHEREOF, each of the undersigned has executed this Asset Purchase Agreement as an agreement as of the Effective Date.

BUYER:

AMYL THERAPEUTICS SRL

By: _____

Name: _____

Title: _____

SELLER:

PROCLARA BIOSCIENCES INC.

By: Kenneth A. Buckfire

Name: _____

Title: Director, Treasurer & Secretary



Schedule 2
Assigned Patents

Case Number	Country	Status	Application Number	Filing Date	Publication Number	Patent Number	Issue Date	Title
NP4A	AUSTRALIA	GRANTED	2012346056	06/13/2014		2012346056	06/07/2018	Use of P3 of bacteriophage as amyloid binding agents
NP4A	BRAZIL	PENDING	BR112014013086-8	05/29/2014				Use of P3 of bacteriophage as amyloid binding agents
NP4A	CANADA	GRANTED	2857539	05/29/2014	2857539	2857539	08/03/2021	Use of P3 of bacteriophage as amyloid binding agents
NP4A	CHINA	PENDING	201280066659.6	07/10/2014	104093414			Use of P3 of bacteriophage as amyloid binding agents
NP4A	EPO PATENT	GRANTED	12799008.3	06/20/2014	2785364	2785364	01/09/2019	Use of P3 of bacteriophage as amyloid binding agents
NP4A	EURASIAN PAT SY	GRANTED	201491063	06/27/2014	201491063	029602	04/30/2018	Use of P3 of bacteriophage as amyloid binding agents
NP4A	FRANCE	GRANTED	12799008.3	06/20/2014	2785364	2785364	01/09/2019	Use of P3 of bacteriophage as amyloid binding agents
NP4A	GERMANY	GRANTED	12799008.3	06/20/2014	2785364	2785364	01/09/2019	Use of P3 of bacteriophage as amyloid binding agents
NP4A	HONG KONG	GRANTED	14111367.6	11/11/2014	1197655	1197655	02/14/2020	Use of P3 of bacteriophage as amyloid binding agents
NP4A	INDIA	PENDING	4587/CHENP/2014	06/18/2014				Use of P3 of bacteriophage as amyloid binding agents
NP4A	INDONESIA	GRANTED	P-00201403872	06/27/2014		IDP000062006	08/29/2019	Use of P3 of bacteriophage as amyloid binding agents
NP4A	IRELAND	GRANTED	12799008.3	06/20/2014	2785364	2785364	01/09/2019	Use of P3 of bacteriophage as amyloid binding agents
NP4A	ISRAEL	GRANTED	232867	05/29/2014		232867	04/01/2020	Use of P3 of bacteriophage as amyloid binding agents
NP4A	JAPAN	GRANTED	2014-543617	05/26/2014		6220344	10/06/2017	Use of P3 of bacteriophage as amyloid binding agents

PATENT

REEL: 062952 FRAME: 0811

NP4A	JAPAN	GRANTED	2017-074284	04/04/2017	2017-122124	6440765	11/30/2018	Use of P3 of bacteriophage as amyloid binding agents
NP4A	LIECHTENSTEIN	GRANTED	12799008.3	06/20/2014	2785364	2785364	01/09/2019	Use of P3 of bacteriophage as amyloid binding agents
NP4A	MEXICO	GRANTED	MX/A/2014/006337	05/27/2014		362175	01/07/2019	Use of P3 of bacteriophage as amyloid binding agents
NP4A	NEW ZEALAND	PENDING	724392	09/15/2016				Use of P3 of bacteriophage as amyloid binding agents
NP4A	PHILIPPINES	GRANTED	1-2014-501200	05/28/2014		1-2014-501200	04/19/2021	Use of P3 of bacteriophage as amyloid binding agents
NP4A	SINGAPORE	PENDING	10201709849T	11/28/2017				Use of P3 of bacteriophage as amyloid binding agents
NP4A	SOUTH AFRICA	GRANTED	2014/03863	05/27/2014		2014/03863	03/27/2019	Use of P3 of bacteriophage as amyloid binding agents
NP4A	SWITZERLAND	GRANTED	12799008.3	06/20/2014	2785364	2785364	01/09/2019	Use of P3 of bacteriophage as amyloid binding agents
NP4A	UNITED KINGDOM	GRANTED	12799008.3	06/20/2014	2785364	2785364	01/09/2019	Use of P3 of bacteriophage as amyloid binding agents
NP4A	USA	GRANTED	14/361157	05/28/2014	0335016	9493515	11/15/2016	Use of P3 of bacteriophage as amyloid binding agents
NP4A	USA	GRANTED	14/797724	07/13/2015	0009766	9493516	11/15/2016	Use of P3 of bacteriophage as amyloid binding agents
NP4A	USA	GRANTED	15/288237	10/07/2016	0115311	10151762	12/11/2018	Use of P3 of bacteriophage as amyloid binding agents
NP4A	VIETNAM	PENDING	1-2014-02078	06/25/2014	40000			Use of P3 of bacteriophage as amyloid binding agents
NP4B	ALBANIA	GRANTED	13776674.7	04/30/2015	2906235	AL/P/2017/534	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	AUSTRALIA	GRANTED	2013327472	04/30/2015		2013327472	02/08/2018	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS

NP4B	AUSTRIA	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	BELGIUM	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	BOSNIA/HERZEGOV	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	BRAZIL	PENDING	BR112015007424-3	04/01/2015				USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	BULGARIA	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	CHINA	GRANTED	201380061794.6	05/27/2015	104870008	ZL201380061794.6	10/01/2019	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	CROATIA	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	CYPRUS	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	CZECH REPUBLIC	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	DENMARK	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	EPO PATENT	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS

PATENT

REEL: 062952 FRAME: 0813

NP4B	ESTONIA	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	EURASIAN PAT SY	GRANTED	201590690	04/30/2015	201590690	033666	11/14/2019	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	FINLAND	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	FRANCE	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	GERMANY	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	GREECE	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	HONG KONG	GRANTED	16101718.1	02/18/2016	1213775	1213775	05/04/2018	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	HUNGARY	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	ICELAND	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	IRELAND	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	ISRAEL	GRANTED	238021	03/30/2015		238021	10/01/2019	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS

PATENT

REEL: 062952 FRAME: 0814

NP4B	ITALY	GRANTED	502017000113714	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	JAPAN	GRANTED	2015-534813	03/31/2015		6283366	02/02/2018	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	KOREA (SOUTH)	GRANTED	10-2015-7011456	04/30/2015		10-2101258	04/09/2020	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	LATVIA	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	LIECHTENSTEIN	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	LITHUANIA	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	LUXEMBOURG	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	MALTA	GRANTED	13776674.7	04/30/2015	2906235	EP35209/2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	MEXICO	GRANTED	MX/A/2015/004119	03/31/2015		358755	09/03/2018	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	MONACO	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	NETHERLANDS	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS

PATENT

REEL: 062952 FRAME: 0815

NP4B	NEW ZEALAND	GRANTED	706838	04/30/2015		706838	10/03/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	NORTH MACEDONIA	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	NORWAY	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	POLAND	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	PORTUGAL	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	REP OF MONTENEG	GRANTED	13776674.7	04/30/2015	2906235	ME-P-2017-215	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	REP OF SERBIA	GRANTED	13776674.7	04/30/2015	2906235	P-2017/0941	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	ROMANIA	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	SAN MARINO	GRANTED	13776674.7	04/30/2015	2906235	SM-T-201700473	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	SLOVAK REPUBLIC	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	SLOVENIA	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS

PATENT

REEL: 062952 FRAME: 0816

NP4B	SOUTH AFRICA	GRANTED	2015/02940	04/29/2015		2015/02940	11/29/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	SPAIN	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	SWEDEN	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	SWITZERLAND	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	TAIWAN	GRANTED	102135558	10/01/2013	1613212	1613212	02/01/2018	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	TURKEY	GRANTED	13776674.7	04/30/2015	2906235	2017/13507	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	UNITED KINGDOM	GRANTED	13776674.7	04/30/2015	2906235	2906235	07/19/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	USA	GRANTED	14/432861	04/01/2015	0376239	9688728	06/27/2017	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	USA	GRANTED	15/587180	05/04/2017	0305975	10208090	02/19/2019	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	USA	GRANTED	15/975328	05/09/2018	2018-0354994	10526377	01/07/2020	USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS
NP4B	VENEZUELA	PENDING	2013-001235	10/01/2013				USE OF P3 OF BACTERIOPHAGE FUSION PROTEINS AS AMYLOID BINDING AGENTS

PATENT

REEL: 062952 FRAME: 0817

NP6	AUSTRALIA	GRANTED	2014274253	12/21/2015		2014274253	09/27/2018	POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY
NP6	EPO PATENT	GRANTED	14737355.9	11/16/2015	3003349	3003349	12/12/2018	POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY
NP6	FRANCE	GRANTED	14737355.9	11/16/2015	3003349	3003349	12/12/2018	POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY
NP6	GERMANY	GRANTED	14737355.9	11/16/2015	3003349	3003349	12/12/2018	POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY
NP6	LIECHTENSTEIN	GRANTED	14737355.9	11/16/2015	3003349	3003349	12/12/2018	POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY
NP6	SWITZERLAND	GRANTED	14737355.9	11/16/2015	3003349	3003349	12/12/2018	POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY
NP6	UNITED KINGDOM	GRANTED	14737355.9	11/16/2015	3003349	3003349	12/12/2018	POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY
NP6	USA	GRANTED	14/894272	11/25/2015	0115223	9988444	06/05/2018	POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY

NP7	EPO PATENT	GRANTED	15831011.0	06/22/2017	3227313	3227313	02/09/2022	Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal
NP7	HONG KONG	PENDING	18104737.0	04/11/2018	1249520			Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal
NP7	JAPAN	GRANTED	2017-529043	05/31/2017		6730988	07/07/2020	Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal
NP7	USA	PENDING	16/905128	06/18/2020	2021-0015895			Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal
NP7	USA	GRANTED	15/532820	06/02/2017	2018-0207231	10722551	07/28/2020	Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal

PATENT

REEL: 062952 FRAME: 0819



33/2

11

■■■■■■■■■■

██████████

■ [REDACTED]
[REDACTED]

■ [REDACTED]

[REDACTED] [REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]